1. American Diabetes Association. Diabetes resources. Available at: www.diabetes.org. Accessed July 15, 2002.
2.
2. Warram JH, Sigal RJ, Martin BC, et al. Natural history of impaired glucose tolerance: follow-up at Joslin Clinic. Diabetic Med.1996;13:S40-S45.
3.
3. American Heart Association. The heart of diabetes: understanding insulin resistance. Available at: http.//216.185.112.5/presenter.jhtrnl?identifier=11243. Accessed March 27, 2002.
4.
4. Goutham R.Insulin resistance syndrome. Am Farn Physician. 2001;63: 1159-1166.
5.
5. Warram JHAMartin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type 11 diabetes in the offspring of diabetic patients. Ann Intern Med.1990;113: 909-915.
6.
6. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev.1995;75:473-486.
7.
7. Plutzky J.Insulin resistance, diabetes and cardiovascular disease: emerging role for PPAR pathways. Cardiology. 2001;2(special ed): 41-47.
8.
8. Haffner SKMykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation. 2000;101:975-975.
9.
9. National Diabetes Educator Program. "If you have diabetes, know your blood sugar numbers." May 2002. Available at: www.ndep.nigh.gov. Accessed July 12, 2002.
10.
10. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002;8:5-10.
11.
11. Stratton IM, Adler Al, Neil HAW, et al, on behalf of the UK Prospective Diabetes Study Group. Association of glycemic with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321: 405-412.
12.
12. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668-2668.
13.
13. Turner RC, Cull CA, Frighi V, Holman RR, on behalf of the UK Prospective Diabetes Study Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
14.
14. Mokdad AH, Ford ES, Bowman, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289:76-79.
15.
15. National Diabetes Education Program. Guiding principles for diabetes care for health care providers and people with diabetes. Available at: http://ndep.nih.gov/materials/pubs/guiding-principles/provider.htm. Accessed January 13, 2003.
16.
16. Harris Ml, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999;22:403-408.
17.
17. Agency for Health Care Administration. Diabetes self-management training. July 2002. Available at: http://www.fdhc.state.fl.us/diabetes/self-management.shtml. Accessed July 15, 2002.
18.
18. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA. 2000;283:1695-1702.
19.
19. Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus mefformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev.2002;18: 127-134.
20.
20. White JR Jr, Campbell RK, Yarborough PC. Pharmacologic therapies. In: Franz MJ, ed. A Core Curriculum for Diabetes Education. 4th ed.Chicago: American Association of Diabetes Educators; 2003: 91-149.
21.
21. Claxton AJ, Cramer J, Pierce C.A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
22.
22. US Food and Drug Administration. CDER new and generic drug approvals: 1998-2002. Available at: http://www.fda.gov/cder/approval/index.htm. Accessed November 19, 2002.
23.
23. Einhorn D, Rendell M, Rosenzweig J, et al, for the Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000; 22:1395-1409.
24.
24. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/ metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab. 2002;4:201-208.
